- Status:
- Red
- Decision Date:
- July 2022
Comments
RED:
- NICE TA833 - Zanubrutinib for treating Waldenstrom’s macroglobulinaemia. NHSE
commissioned. (Decision date - November 2022)
- Zanubrutinib for treating chronic lymphocytic leukaemia. NHSE commissioned. (NICE TA expected - Late November 2023)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
search again